Postmenopausal Osteoporosis Drugs Market to See Massive Growth by 2029

Postmenopausal Osteoporosis Drugs Market is anticipated to grow at a significant CAGR during the forecast period. Postmenopausal osteoporosis is a heterogeneous disorder caused due to progressive loss of bone tissue. It can occur either after natural or surgical menopause and leads to fracture within 15 to 20 years from the cessation of ovarian function. The major factor for the growth of the market is the increasing prevalence of postmenopausal osteoporosis across the globe.

According to the Endocrine Society, approximately 1 in 10 women over the age of 60 are affected by osteoporosis. Additionally, one in two postmenopausal women has osteoporosis while most women suffer a fracture during their lifetime. Hence, the increasing prevalence of postmenopausal osteoporosis is driving the demand for postmenopausal osteoporosis drugs which in turn is driving the growth of the market. Furthermore, the market is growing due to ongoing R&D. For instance, in July 2019, Sandoz (Novartis) announced the first patient enrolled in ROSALIA. It is an integrated Phase I/III clinical study for its proposed biosimilar denosumab. Denosumab is used for the treatment of a variety of conditions such as osteoporosis in postmenopausal women.

Some major players in the market include Eli Lilly and Co., Pfizer, Inc., and Merck & Co., Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in April 2019, Amgen announced the approval of Evenity (romosozumab-aqqg) from the US FDA. It is used for the treatment of osteoporosis in postmenopausal women at high risk of breaking a bone.

To Request a Sample of our Report on Postmenopausal Osteoporosis Drugs Market:   https://www.omrglobal.com/request-sample/postmenopausal-osteoporosis-drugs-market

Market Coverage

  • The market number available for – 2022-2030
  • Base year- 2022
  • Forecast period- 2023-2030

Segment Covered- 

  • By Type
  • By Application

Regions Covered-

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape– Eli Lilly and Co., Pfizer, Inc., and Merck & Co., Inc., among others.

Postmenopausal Osteoporosis Drugs Market Report by Segment

By Type 

  • Antiresorptive Medications
  • Anabolic Medications

By Application

  • Hospital
  • Pharmacy
  • Others

A full Report of Postmenopausal Osteoporosis Drugs Market is Available @   https://www.omrglobal.com/industry-reports/postmenopausal-osteoporosis-drugs-market

 Postmenopausal Osteoporosis Drugs Market Report by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe

Asia-Pacific

  • India
  • China
  • Japan
  • South Korea
  • Rest of APAC

Rest of the World

  • Latin America
  • Middle East & Africa

Reasons to buy from us –

  1. We cover more than 15 major industries, further segmented into more than 90 sectors.
  2. More than 120 countries are for analysis.
  3. Over 100+ paid data sources mined for investigation.
  4. Our expert research analysts answer all your questions before and after purchasing your report.

About Orion Market Research 

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no:  +91 7803040404